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Abstract. Smad4 is a critical regulator of transforming growth 
factor (TGF)-β signaling and is defective in numerous human 
cancers. In total, 30% of pancreatic cancers harbor a homozy-
gous deletion of Smad4. The human pancreatic cancer cell line, 
BxPC3, has been reported to be Smad4-null due to a homo-
zygous deletion and has been widely used as a Smad4-null 
model. The present study reports that Smad4 DNA is present in 
BxPC3 cells, and under conditions of suppressed mammalian 
target of rapamycin complex 1 (mTORC1) and phosphati-
dylinositol-3-kinase, a truncated Smad4 protein is expressed. 
While a high level of Smad4 protein can be expressed in these 
cells, the cells do not respond to TGF-β. The Smad4 defect in 
BxPC3 cells likely occurs via translocation rather than deletion 
as previously reported.
Introduction
Smad proteins are intracellular mediators of transforming 
growth factor-β (TGF-β) and bone morphogenetic protein 
signaling pathways necessary for the regulation of a variety of 
critical processes, including embryonic development, fibrosis, 
tumor development, immune function and wound healing (1,2). 
Genomic sequencing has revealed numerous defects in the 
TGF-β signaling pathway of human pancreatic cancers (3). 
Smad4, also known as DPC4 (deleted in pancreatic carcinoma, 
locus 4), was first isolated and identified in pancreatic cancer on 
human chromosome 18q21.1 (4). Hahn et al reported that ~90% 
of human pancreatic cancers show allelic loss at chromosome 
18q. Deletion of chromosome 18q, which encompasses the 
Smad4 region, significantly affects the prognosis of pancreatic 
cancer (4). Individuals with pancreatic cancer positive for 
Smad4 have shown a higher survival rate compared with those 
with pancreatic cancers negative for Smad4 (5). These findings 
indicate that the presence of Smad4 is critical in the develop-
ment and treatment of human pancreatic cancers.
Chromosomal deletions occur in a number of cancers 
causing either the absence of the gene or loss of its function (6). 
According to the National Human Genomic Research Institute 
and the National Center for Biotechnology Information, trans-
location is defined as a type of chromosomal abnormality in 
which a chromosome breaks and a portion of it reattaches to 
a different chromosome. Studies have shown that >90% of 
human cancers possess a certain type of clonal cytogenetic 
change (6-8). The most widely described chromosomal abnor-
mality involving chromosomal translocation is the Philadelphia 
chromosome (9,10). Produced from the fusion of chromosome 9 
and a truncated chromosome 22, the Philadelphia chromosome 
leads to an oncogenic BCR-ABL gene, which is responsible 
for the development of chronic myelogenous leukemia (11-14). 
Thus, chromosomal translocations can lead to the formation of 
new genes caused by the merging or ablation of existing genes 
that contribute to the oncogenic phenotype.
Characterizing translocated genes involves the use 
of banding techniques originally described by Rowley in 
1973 (10). However, studies used to identify homozygous dele-
tions on chromosome 18q in pancreatic cancer cells utilized 
PCR-based assays that focused mainly on characterizing a 
specific region of chromosome 18q where homozygous dele-
tions commonly occur, 18q21.1 (4,6). While deletion mapping 
can identify missing areas of a chromosome, in the case of 
Smad4 in BxPC3 cells, it does not take into consideration 
deletion due to translocation. While investigating the synthetic 
lethal interactions between the inhibition of as mamma-
lian target of rapamycin complex 1 (mTORC1) and TGF-β 
signaling pathways in Smad4-null BxPC3 cells, the expression 
of a Smad4-like protein was identified. The present study 
therefore investigated whether the Smad4 gene is actually 
present in BxPC3 cells, a pancreatic cancer cell line widely 
used to represent a Smad4-null genotype.
Materials and methods
Cell lines and cell culture conditions. The BxPC3 and Panc1 
cells used in this study were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA) and 
were maintained in Roswell Park Memorial Institute (RPMI) 
medium and Dulbecco's modified Eagle's medium (DMEM), 
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respectively, supplemented with 10% fetal bovine serum 
(Hyclone, Waltham, MA, USA). BxPC3 cells were also obtained 
from a stock maintained by Dr Murray Korc (University of 
Indiana, Indianapolis, IN, USA). For transfection of siRNA, 
the cells were plated at a density of 105 cells/60-mm plate 
24 h prior to transfection. All transfections were performed 
using Lipofectamine 2000 (Gibco-BRL, Carlsbad, CA, USA) 
according to the manufacturer's instructions.
Materials. Rapamycin was obtained from LC Laboratories 
(Woburn, MA, USA). The phosphatidylinositol-3-kinase (PI3K) 
inhibitor, LY294002, and Wortmannin were obtained from 
Cell Signaling Technology, Inc. (Danvers, MA, USA). Total 
Smad2 (product number 5339S, monoclonal rabbit IgG), total 
Smad3 (product number 9523P, monoclonal rabbit IgG) and 
Smad4 (product number 9515, monoclonal rabbit IgG) primary 
antibodies were obtained from Cell Signaling Technology, 
Inc. (Danvers, MA, USA), and the glyceraldehyde 3-phos-
phate dehydrogenase antibody was obtained from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA, USA). Smad4 siRNA and 
non-targeted negative control siRNA duplexes were obtained 
from Santa Cruz Biotechnology Inc. Smad4 primers were 
designed and synthesized by IDT (Coralville, IA, USA). A 
DNeasy Blood and Tissue kit was obtained from Qiagen (Hilden, 
Germany) and a Phusion High Fidelity DNA Polymerase kit 
was obtained from New England Biolabs (Ipswich, MA, USA). 
Western blot analysis. Proteins were extracted from cultured 
cells in modified radioimmunoprecipitation assay buffer 
(Upstate Biotechnology Inc., Lake Placid NY, USA). Equal 
amounts of protein were subjected to SDS-PAGE separating 
gels. Electrophoresed proteins were then transferred to nitro-
cellulose and subjected to western blot analysis as described 
previously (15). The results of the western blot analysis were 
quantified using ImageJ software version 1.47 (NIH, Bethesda, 
MD, USA)
PCR. Genomic DNA was extracted from the cells using the 
Qiagen DNeasy Blood and Tissue kit. PCR amplification was 
performed using primers specific to Smad4 DNA and the Phusion 
High Fidelity DNA Polymerase kit was used to determine the 
presence of Smad4 in each cell line. Exon 1: Forward primer, 
5'-ATGCTCAGTGGCTTCTCGACAAGTTG-3' and reverse 
primer, 3'-GGGCTTTTTAAAGCCTCTGCACCAG-5'. 
Exon 2: forward primer, 5'-CCTTGCAACGTTAGCTGT TGT-3' 
and reverse primer, 3'-TGAAGCCTCCCATCCAATGTT 
CTC-5'. Exon 12: forward primer, 5'-GTTGATGTGGATACT 
TTTCACACCG-3' and reverse primer, 3'-CTACCACAAAGC 
TGGCCTCTACCA-5'.
Smad4 siRNA duplexes. Smad4 siRNA (human) is a pool 
of three different siRNA duplexes: Exon from nucleic 
acids 788-962, with sense, GCAUCGACAGAGACAUACAtt, 
and antisense, UGUAUGUCUCUGUCGAUGCtt. Exon from 
nucleic acids 2277-3086, with sense, GAUGACUGUUGAUGA 
AGUAtt, and antisense, UACUUCAUCAACAGUCAUCtt. 
Exon f rom nucleic acids 2277-3086, with sense, 
CAAGGUUGGUUGCUAAGAAtt and antisense, UUCUUA 
GCAACCAACCUUGtt. All sequences are provided in 5'→3' 
orientation.
Results
PI3K and mTOR complex 1 (mTORC1) inhibition induces expres‑
sion of Smad4 in BxPC3 cells. Defects in TGF-β signaling have 
been reported for the majority of pancreatic cancers, with dele-
tions or mutations in Smad4 being most prevalent (3,4). Smad4 is 
a member of the Smad family and plays a pivotal role in mediating 
the downstream effects of the TGF-β signaling pathway (16,17). 
As a tumor suppressor, Smad4 regulates TGF-β-mediated epithe-
lial cell growth or inhibition (18). Rapamycin has been reported 
to activate TGF-β signaling by mediating the nuclear transloca-
tion of activated Smad2/3 in complex with Smad4, while having 
no effect on the total protein levels (19). Rapamycin has also 
been reported to induce a negative feedback loop that activates 
the PI3K signaling pathway, which can block the expression 
and activation of Smad3, thus inhibiting the TGF-β signaling 
pathway (20). The present study therefore aimed to determine 
the effect of rapamycin on Smad2, Smad3 and Smad4 protein 
levels in Panc1 and BxPC3 cells. Data shown in Fig. 1A indicate 
that rapamycin alone or in combination with the PI3K inhibitor, 
LY294002, does not affect the expression levels of Smad2, 3 or 4 
in Smad4 wild-type Panc1 cells. Sole treatment with rapamycin 
also does not affect the Smad2, 3 or 4 protein levels in BxPC3 
cells; expression of Smad4 protein was not expected given the 
previously reported absence of Smad4 DNA in BxPC3 cells (4). 
As expected, Smad4 protein was not detected in the BxPC3 
cells (Fig. 1B, left panel). However, upon dual treatment with 
rapamycin and the PI3K inhibitor, LY294002, or Wortmannin 
in the BxPC3 cells, a protein recognized by a Smad4 primary 
antibody was expressed (Fig. 1B, middle and right panels). This 
treatment had no effect on the level of Smad2 or Smad3 in the 
BxPC3 cells. These data indicate that under conditions where 
mTORC1 and PI3K signaling pathways are inhibited, a protein 
containing a similar amino acid sequence to that of wild-type 
Smad4 is expressed in BxPC3 cells.
siRNA for Smad4 decreases the Smad4‑like protein in BxPC3 
cells. The present study showed that Smad4 is detected under 
stress conditions in BxPC3 cells (Fig. 1). To further confirm that 
the protein expressed upon dual inhibition of the mTORC1 and 
PI3K signaling pathways in BxPC3 cells is Smad4, Panc1 and 
BxPC3 cells were pretreated with Smad4 siRNA followed by 
dual treatment with rapamycin and LY294002. Data in Fig. 2 
show that Smad4 siRNA inhibits the expression of Smad4 in 
Panc1 cells (Fig. 2A), as well as the stress-induced Smad4-like 
protein in BxPC3 cells (Fig. 3B). The human Smad4 siRNA 
is a pool of three different siRNA duplexes, one from nucleic 
acids 788-962 (exon 3) and two from nucleic acids 2277-3086 
(exon 12). Therefore, this data indicates that the abrogated expres-
sion of Smad4 in BxPC3 cells is linked to the siRNA duplexes 
that target either the exon 3 or 12 region of Smad4 DNA. Repeat 
experiments performed on the BxPC3 cells obtained from Dr 
Murray Korc showed the same pattern (data not shown). 
Smad4 DNA is amplified in exon 12 of BxPC3 pancreatic cancer 
cells. Proteins are generated via transcription and then transla-
tion from the subsequent DNA sequence. Therefore, proteins 
cannot be made without the presence of the corresponding DNA 
sequence. It has been previously reported that Smad4 DNA is 
amplified in Panc1 but not BxPC3 cells (4,21). It is important 
ONCOLOGY LETTERS  7:  1165-1168,  2014 1167
to note that Smad4 DNA contains 12 exons, which encode for 
the 552-amino acid Smad4 protein; exon 12 being the largest, 
measuring 6.787 kb (Fig. 3A) (22). Therefore, to determine the 
source of the inducible Smad4 protein in the BxPC3 cells, DNA 
extracted post-treatment with rapamycin and LY294002 was 
analyzed by PCR. Exon 1 of Smad4 has been previously used 
to identify the presence or absence of the gene (4). As shown 
in Fig. 3B, DNA was amplified in the Panc1 cells for exon 1, 
2 and 12, the largest primer derived exons, in the presence of 
serum. However, when analyzing the BxPC3 cells, a DNA 
Figure 1. PI3K and mTORC1 inhibition induces expression of Smad4 in BxPC3 cells. (A) Panc-1 cells were plated at 105 cells/60-mm plate in 10% serum. 
(A) After 24 h, the cells were shifted to media containing 10% serum with the indicated concentration of rapamycin (Rapa) (A, left panel). After another 4 h, the 
levels of Smad4, Smad2, Smad3 and GAPDH were analyzed by western blotting. Panc-1 cells were plated at 105 cells/60-mm plate in 10% serum. After 24 h, 
the cells were shifted to media containing 10% serum and LY294002 (50 µM) for 1 h (A, right panel). The cells were then treated with the indicated concentra-
tion of Rapa. After another 4 h, the levels of Smad4, Smad2, Smad3 and GAPDH were analyzed by western blotting. (B) BxPC3 cells were plated as above 
and treated with the indicated concentrations of Rapa for 4 h (left panel) or LY294002 (50 µM; middle panel) or Wortmannin (1 µM; right panel) for 1 h. Cells 
initially treated with LY294002 or Wortmannin were then treated with the indicated concentration of Rapa. After 4 h, the levels of Smad4, Smad2, Smad3 and 
GAPDH were analyzed by western blotting. Western blots are representative of at least three independent experiments. PI3K, phosphatidylinositol-3-kinase; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mTORC1, mammalian target of rapamycin complex 1.
Figure 2. siRNA for Smad4 decreases the Smad4-like protein in BxPC3 cells. (A) Panc-1 cells were plated in media containing 10% serum for 24 h. The cells were 
then transfected with either control or Smad4 siRNA. After 48 h, the Panc1 cells were placed in fresh media containing 10% serum and LY294002 (50 µM) for 1 h, 
then rapamycin (Rapa; 20 µM) for 4 h at the indicated concentrations. The total lysate was analyzed by western blotting for levels of Smad4, Smad2, Smad3 and 
GAPDH. Western blots are representative of at least two independent experiments. (B) BxPC3 cells were plated in media containing 10% serum for 24 h. The cells 
were then transfected with either control or Smad4 siRNA. After 24 h, the BxPC3 cells were placed in fresh media containing 10% serum and LY294002 (50 µM) 
for 1 h, then Rapa (20 µM) for 4 h at the indicated concentrations. The cells were then collected, lysed and analyzed by western blotting for levels of Smad4, total 
Smad2, total Smad3 and GAPDH. Western blots are representative of at least two independent experiments. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Figure 3. Smad4 DNA is amplified in exon 12 of BxPC3 pancreatic cancer cells. (A) Schematic of Smad4 gene. (B) Panc1 and BxPC3 cells were plated at a density 
of 105 cells/60-mm plate. After 24 h, the cells were provided with fresh media containing 10% serum, and DNA from the Panc1 and BxPC3 cells was extracted using 
a Quigen DNA extraction kit. The acquired DNA was analyzed by PCR. PCR analyses are representative of at least two independent experiments. (C) BxPC3 cells 
were plated as stated above and then shifted to media containing 10% serum and LY294002 (50 µM) or Wortmannin (1 µM) for 1 h.  The cells were then treated with 
the indicated concentration of rapamycin (Rapa). After 4 h, the levels of Smad4 were analyzed by western blotting. Panc-1 was used as a positive control.
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amplification band was only observed for exon 12 (Fig. 3B). 
Given that only the Smad4 DNA fragment corresponding to 
exon 12 is present in BxPC3 cells, it is possible that the protein 
expressed post-treatment with rapamycin and the PI3K inhibi-
tors is a truncated form of Smad4. As with the Philadelphia 
chromosome, depending on the precise translocated region of 
the Smad4 gene, the molecular weight of the corresponding 
protein can be altered (14). Therefore, to determine the relative 
size of Smad4 expressed in the BxPC3 cells, the cells that were 
dually treated with high-dose rapamycin and LY294002 or 
Wortmannin were analyzed for Smad4 on the same western blot 
gel using Panc-1 cells as a positive control. As shown in Fig. 3C, 
Smad4 in the BxPC3 cells had a slightly faster electrophoretic 
mobility than wild-type Panc-1 Smad4. Taken together, these 
data indicate that BxPC3 cells express an inducible truncated 
version of the Smad4 protein, encoded mostly in exon 12 of 
Smad4 DNA. 
Discussion
BxPC3 cells are reported to have a homozygous deletion on 
chromosome 18q, which encompasses the coding region for 
Smad4/DPC4, 18q21.1 (4). PCR-assays, along with the combi-
nation of deletion and physical mapping, were employed to 
identify the homozygous deleted regions of chromosome 18q 
and resulted in the identification of Smad4 as a tumor 
suppressor located at chromosome 18q21.1 (4,6). Hahn et al 
reported that chromosomal region 18q21.1 is deleted in 30% 
of pancreatic cancers, including in BxPC3 cells. Homozygous 
deletion of Smad4 has been correlated with the loss of expres-
sion of the corresponding protein (23). Smad4 plays a pivotal 
role in regulating TGF-β signaling and can function as a tumor 
suppressor or promoter (5,24).
The homozygous loss of Smad4 has been the basis for use 
of BxPC3 cells as a model for pancreatic cancer with defec-
tive TGF-β signaling. We previously reported that TGF-β was 
unable to rescue BxPC3 cells from rapamycin-induced cell 
death, as was the case in the Smad4 wild-type Panc1 pancreatic 
cancer cells (15) indicating that BxPC3 pancreatic cancer cells 
are not responsive to TGF-β. However, in the present study, we 
suggest that the basis for defective TGF-β signaling in BxPC3 
cells is not due to the homozygous deletion of Smad4, in that 
much of the Smad4 gene is present and expressed in response 
to the stress of mTORC1 and PI3K suppression. Thus, it is more 
likely that the loss of the Smad4 gene on chromosome 18q is due 
to a translocation rather than homozygous deletion. Whether the 
truncated Smad4 protein has any phenotypic impact on BxPC3 
cells is not known, however, it appears that BxPC3 cells do not 
respond to TGF-β. 
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